Company: XAIR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001493152-25-005678
Chunk: 27

Company: Beyond Air, Inc.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
810) 
    $(965) 
    $(29,775)
  
    Net assets 
    $16,528  
    $10,658  
    $27,186 
  
    Non-controlling interests 
    $-  
    $2,138  
    $2,138 

The
following table summarizes segment financial performance by business segment for the nine months ended December 31, 2024:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 
  
    Revenue 
    $2,553  
    $-  
    $2,553 
  
    Net loss for the nine months ended December 31, 2024 
    $(31,293) 
    $(9,123) 
    $(40,416)

The
following table summarizes segment financial performance by business segment for the three months ended December 31, 2024:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 
  
    Revenue 
    $1,072  
    $-  
    $1,072 
  
    Net loss for the three months ended December 31, 2024 
    $(11,833) 
    $(1,500) 
    $(13,333)

The
following table summarizes segment financial performance by business segment for the nine months ended December 31, 2023:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 

    Revenue 
    $689  
    $-  
    $689 
  
    Net loss for the nine months ended December 31, 2023 
    $(33,721) 
    $(16,018) 
    $(49,739)

The
following table summarizes segment financial performance by business segment for the three months ended December 31, 2023:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 
  
    Revenue 
    $391  
    $-  
    $391 
  
    Net loss for the three months ended December 31, 2023 
    $(12,065) 
    $(5,193) 
    $(17,258)
  
    Net loss  
    $(12,065) 
    $(5,193) 
    $(17,258)

Research
and Development

Research
and development expenses are charged to the unaudited condensed consolidated statements of